Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease by Seini Moimoi | May 20, 2025 | Portfolio News
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) by Seini Moimoi | May 20, 2025 | Portfolio News
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma by Seini Moimoi | May 19, 2025 | Portfolio News
Cohere Health Secures $90M Series C to Expand AI-Powered Platform Transforming Health Plan Clinical Decision-Making by Seini Moimoi | May 14, 2025 | Portfolio News
Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025 by Seini Moimoi | May 3, 2025 | Portfolio News
Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025 by Seini Moimoi | Apr 28, 2025 | Portfolio News
